Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:30PM ET

February 7, 2018

RALEIGH, N.C., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq:INNT) a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced company executives are scheduled to present at the BIO CEO & Investor Conference on Monday, February 12, 2018, at 3:30 PM ET in the Wilder presentation room at the New York Marriott Marquis located at 1535 Broadway in Times Square.

About Innovate Biopharmaceuticals, Inc.:
Innovate is a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutic drugs. Innovate's lead drug candidate, larazotide acetate (INN-202), has a mechanism of action which decreases intestinal permeability and regulates tight junctions by reducing antigen trafficking across intestinal epithelial cells. In several autoimmune diseases, including celiac disease, nonalcoholic steatohepatitis (NASH), inflammatory bowel diseases (IBD, Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD) and others, intestinal permeability is increased, also referred to as "leaky gut," and to our knowledge, larazotide is the only drug in clinical testing which reduces permeability.

In celiac disease, larazotide is the only drug which has successfully met the primary endpoint with statistical significance in a 342-patient Phase 2b efficacy clinical trial. Innovate successfully completed the End of Phase 2 Meeting with the FDA in 2017 and is preparing for larazotide to begin Phase 3 clinical trials for celiac disease around mid-2018. In clinical trials testing more than 800 patients, larazotide demonstrated a favorable safety profile comparable to placebo, especially due to its lack of systemic absorption from the small intestines. Larazotide has also received Fast Track designation from the FDA for celiac disease.

Innovate Biopharmaceuticals, Inc.
Kendyle Woodard
Tel: 919-275-1933 x 1
Email: investor.relations@innovatebiopharma.com
www.innovatebiopharma.com

Primary Logo

Source: Innovate Biopharmaceuticals, Inc